[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Saxena A, Memauri B, Hasegawa W: Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour. J Clin Pathol; 2005 Mar;58(3):331-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour.
  • Warthin tumours (WT) and malignant lymphomas are only rarely associated, and most are examples of involvement of the lymphoid stroma of WT by a disseminated lymphoma.
  • This report describes a case where excision of a parotid mass led to the initial diagnosis of WT and small lymphocytic lymphoma (SLL).
  • The patient had stage IV A disease and is currently in chemotherapy induced complete remission.
  • [MeSH-major] Adenolymphoma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Jan;113(1):113-9 [10631864.001]
  • [Cites] Histopathology. 1993 Mar;22(3):280-1 [8495960.001]
  • [Cites] Ear Nose Throat J. 1979 Aug;58(8):345-50 [583035.001]
  • [Cites] Pathol Annu. 1979;14 Pt 2:307-24 [583554.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):13-38 [7467121.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2948-50 [7139585.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Hum Pathol. 1985 Apr;16(4):424-7 [3980011.001]
  • [Cites] J Pathol. 1985 Jul;146(3):167-77 [3928854.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):491-6 [3082065.001]
  • [Cites] Pathol Res Pract. 1986 Oct;181(5):615-20 [3786253.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):341-4 [2538052.001]
  • [Cites] Tumori. 1990 Apr 30;76(2):212-5 [2184550.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):974-7 [2394439.001]
  • [Cites] Pathology. 1992 Apr;24(2):60-2 [1322520.001]
  • [Cites] Ear Nose Throat J. 1993 Apr;72(4):264-9, 272-3 [8486105.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • (PMID = 15735173.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770608
  •  go-up   go-down


2. Lenz G, Hiddemann W, Dreyling M: The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer; 2004 Sep 1;101(5):883-93
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
  • Advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL) cannot be cured using conventional chemotherapy.
  • Fludarabine, the most widely used purine analog, exhibits a particularly high level of activity against small lymphocytic lymphoma and chronic lymphocytic leukemia (CLL).
  • Numerous studies have investigated the efficacy of fludarabine as a single agent or in combination with other cytostatic compounds in the treatment of FL and MCL.
  • Fludarabine monotherapy has proven to be particularly effective in the treatment of FL; however, complete responses (CRs) are observed in only approximately 20-40% of all cases.
  • In summary, fludarabine has proven to be a safe and effective agent in the treatment of indolent lymphoma.
  • Consequently, current research efforts have focused on the use of fludarabine-containing combinations in the first-line treatment of FL and MCL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15329894.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 74
  •  go-up   go-down


3. Koffi G, Kouakou B, Ndiaye FS, Ndathz E, Sanogo I, Sangare A: [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. Bull Cancer; 2007 Oct;94(10):902-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
  • [Transliterated title] Caractéristiques thérapeutiques et évolutives des lymphomes folliculaires du Noir africain: expérience de la Côte d'Ivoire.
  • We reported in this study a treatment results about 36 Africans patients with follicular lymphoma.
  • The average age of patients was 18 to 73 years old with a median age at 50.83 years old and a sex ratio of 1.
  • Clinical characteristics of patients are mainly represented by advance stage with 70% of stage III and IV of Ann Arbor classification.
  • Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27.78 and 22.22%.
  • Using varieties of therapeutics regiments, we obtained 41.67% of complete remission.
  • Indeed, the follicular lymphomas constituted by large cells and mixed cells had higher rate of complete remission with respectively 46.67% and 40% in relation with those of small cells with a higher failure rate.
  • After a long period, 25 cases of death have been reported, 5 cases of losing sight and 6 patients are still alive and following treatment.
  • The short survival delay time of our patients didn't permit time to observe transformation case in diffuse large cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cote d'Ivoire. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964984.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP-B protocol; COP protocol 2
  •  go-up   go-down


Advertisement
4. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


5. Choo SP, Lim ST, Wong EH, Tao M: Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy. Onkologie; 2006 Feb;29(1-2):14-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy.
  • PURPOSE: This paper is to determine the clinicopathological features and outcome of patients with breast lymphoma seen at a single institution.
  • PATIENTS AND METHODS: We have reviewed data on 14 patients with breast lymphoma seen at our institution from 1990 to 2003.
  • RESULTS: All patients were female, with a median age of 47.6 years.
  • Diffuse large B-cell lymphoma (DLBCL) was observed in 9 cases, while follicular, Burkitt's, small lymphocytic, MALT and T-cell lymphoma were observed in 1 case each.
  • 5 patients (35.7%) had stage IE disease, 6 patients (42.9%) had stage IIE disease and 3 patients (21.4%) had stage IV disease.
  • Standard CHOP with or without rituximab was given to all patients with aggressive breast lymphoma (n = 10), while 1 patient with Burkitt's lymphoma received a CHOP-based regimen.
  • The 3-year actuarial survival estimate among all 11 patients with aggressive breast lymphoma was 73%.
  • The actuarial 3-year overall survival (OS) estimate for the entire cohort of 14 patients was 76.9%.
  • CONCLUSION: Our results indicate that breast lymphoma is not associated with an inferior outcome when treated with standard CHOP-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Lymphoma / drug therapy. Lymphoma / mortality
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Singapore / epidemiology. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514249.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Xu LP, Huang XJ, Liu DH, Chen YH, Shi HX, Chen DB: [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi; 2007 Dec;46(12):996-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
  • OBJECTIVE: To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT).
  • 9 patients developed PTLD.
  • The morphology of biopsy appeared as small B-lymphocytic lymphoma; there was no response to chemotherapy and the patients died.
  • In the remaining 7 patients it occurred an early stage after HSCT (day 32-78).
  • One patient recovered by reducing immunosuppressive drug therapy combined with MP and one patient recovered by reducing immunosuppressive/antivirus therapy and donor lymphocyte infusion.
  • CONCLUSIONS: Post HSCT PTLD occurs characteristically as disseminated disease with a rapidly progressive and often fulminant course and had a high mortality.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478915.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


7. Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A, Rossi G, Novero D, Gavarotti P, Pileri A: Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia; 2000 Apr;14(4):740-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
  • Long-term outcome, after first line intensified high-dose sequential (i-HDS) chemotherapy, was evaluated in 46 patients, aged < or =65 years, with advanced low-grade lymphoma.
  • Seventeen patients had small lymphocytic lymphoma (SLL), 29 had follicular lymphoma (FL), 10 of them with histologic transformation.
  • (2) sequential administration of high-dose (hd) etoposide, methotrexate, and cyclophosphamide, followed by peripheral blood progenitor cell (PBPC) harvest;.
  • There were two treatment-related deaths; five FL patients had short-lasting response followed by disease progression, five SLL reached a stable PR; overall, 34 patients (74%) reached CR.
  • At a median follow-up of 4.3 years, the estimated 9-year OS and EFS were 84% and 45%, respectively.
  • No significant differences were observed in the OS among patients at low, intermediate or high IPI score, with an estimated OS projection of 95%, 78%, and 75%, respectively.
  • FL had longer survival without evidence of residual disease (9-year EFS: 59%) as compared to SLL patients (8.8-year EFS: 17%); however, both groups had prolonged survival and no need of salvage treatment, as shown by the time to disease progression curve, projected to 66% and 62% for SLL and FL, respectively.
  • The results indicate that hd-approach in low-grade lymphoma:.
  • (1) is associated with longer progression-free survival as compared to conventional therapies;.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Follicular / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764164.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; YL5FZ2Y5U1 / Methotrexate; APO protocol 2; DHAP protocol
  •  go-up   go-down


8. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I: Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther; 2009 Oct;8(10):2821-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with advanced breast cancer frequently develop bone metastases, and at this stage, the disease is considered incurable.
  • Tumors from the sequential treatment group also displayed increased levels of apoptosis, increased expression of bcl2-associated X protein, decreased expression of B-cell chronic lymphocytic leukemia/lymphoma 2, and activation of caspase 3, 8, and 9.
  • Zoledronic acid caused a small reduction in tumor volume, reduced tumor cell proliferation, and decreased expression of cyclins D1 and D3, compared with tumors from animals treated with saline or doxorubicin.
  • Doxorubicin had no effect on tumor growth, cell cycle, or apoptosis in vivo, but did cause increased accumulation of a bisphosphonate in MDA-MB-436 cells in vitro, suggesting that doxorubicin may affect subsequent uptake of zoledronic acid.
  • In support of this, accumulation of unprenylated Rap1A, a surrogate marker of zoledronic acid, was only detected in tumors following sequential treatment, and not following treatment with zoledronic acid alone.
  • Our data are the first to show the specific molecular pathways by which sequential treatment with doxorubicin and zoledronic acid induce tumor cell apoptosis and inhibit proliferation in an in vivo model of breast tumor growth in bone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Diphosphonates / therapeutic use. Doxorubicin / therapeutic use. Imidazoles / therapeutic use
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Bone and Bones / drug effects. Bone and Bones / pathology. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Models, Biological. Osteoclasts / drug effects. Osteoclasts / pathology. Xenograft Model Antitumor Assays


9. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Högberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. Acta Oncol; 2001;40(2-3):135-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
  • This report by The Swedish Council on Technology Assessment in Health Care (SBU) reviews, classifies, and grades the scientific literature on cancer chemotherapy in some major tumour types, describes the practice of chemotherapy in Sweden, compares practice with scientific knowledge, and analyses the costs and cost-effectiveness of chemotherapy.
  • The report is intended primarily for decision-makers at various levels, both practitioners and administrators.
  • For the final evaluation to be as close to the objective truth as possible, a concerted effort was made to guarantee objectivity and thorough assessment of current knowledge about the effects of chemotherapy on the selected cancers.
  • The tumour types selected for this assessment include firstly those types where three investigations had shown an increased use of chemotherapy in Sweden during the latest decade.
  • These were non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, colorectal cancer and urinary bladder cancer.
  • Secondly, the two tumour types comprising the greatest number of patients treated with chemotherapy in Sweden, breast cancer and haematological malignancies, were included.
  • Among the haematological malignancies, the most prevalent ones, acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), Hodgkin's disease (HD), aggressive non-Hodgkin's lymphoma (NHL) of the large B-cell type and indolent NHL of follicular type were evaluated.
  • Thirdly, ovarian cancer was included since chemotherapy has been extensively used and since, at the time of the planning of this overview, a group of very expensive drugs, the taxanes, had preliminarily shown promising results.
  • A wealth of scientific literature has been published on cancer therapy.
  • The review presented in this report is limited to scientific studies judged to be important for evaluating chemotherapy efficacy.
  • The survey of practice of chemotherapy use involved all departments of surgery, urology, gynaecology, internal medicine including haematologic units, pulmonary medicine and general and gynaecologic oncology at 16 hospitals in two health care regions in Sweden, covering 39% of the Swedish population.
  • During the 4 weeks of the survey, all patients with the diagnoses concerned who received chemotherapy were registered.
  • The working group's general conclusions are summarised in the following points: The literature on the effects of chemotherapy is extensive.
  • Chemotherapy has a well-documented role in the curative and palliative treatment of patients with several types of cancer.
  • The use of chemotherapy is of utmost importance for the possibility of cure in certain tumour types.
  • In other tumours, chemotherapy increases the possibility of cure when added to local and regional treatments, particularly surgery.
  • In the instances of no possibility of cure, chemotherapy may to a variable extent improve both patient survival and well-being.
  • In Sweden chemotherapy is largely used in accordance with that documented in the scientific literature.
  • The extent of both over- and under-treatment seems to be limited but cannot be excluded at the individual patient level.
  • The literature-based knowledge is scientifically of lower quality in the most chemotherapy sensitive tumours than in tumours showing more limited sensitivity.
  • In the more sensitive tumours, positive effects on a symptomatic stage and survival were seen several decades ago.
  • In those days, clinical treatment studies did not fulfil the current high quality requirements.
  • Small life-prolonging effects of chemotherapy are sometimes very well documented in large, high quality scientific studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Technology Assessment, Biomedical
  • [MeSH-minor] Cost-Benefit Analysis. Decision Making. Drug Costs. Evidence-Based Medicine. Humans. Sweden

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441927.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


10. Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ: Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J; 2000 May-Jun;6(3):146-50
Hazardous Substances Data Bank. RICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
  • The purpose of this article was to evaluate the antitumor effects of a combination chemotherapy program based on ProMACE (prednisone, methotrexate, doxorubicin [Adriamycin], cyclophosphamide, etoposide) followed by a B cell-specific immunotoxin in the treatment of patients with advanced-stage indolent histology non-Hodgkin's lymphomas.
  • After confirmation of diagnosis and staging evaluation, 44 patients (10 small lymphocytic lymphoma, 27 follicular lymphoma, 7 mantle cell lymphoma; 30 without prior therapy, 14 previously treated) received six cycles of ProMACE-CytaBOM (cytarabine, bleomycin, vincristine [Oncovin], mechlorethamine) combination chemotherapy (with etoposide given orally daily for five days) followed by a 7-day continuous infusion of anti-B4-blocked ricin immunotoxin at 30 microg/kg/day given every 14 days for up to six cycles.
  • A complete response was achieved in 25 of 44 patients (57%), 21 from the chemotherapy alone, 3 converted from partial to complete response with the immunotoxin, and 1 patient became a complete responder after a surgical procedure to remove an enlarged spleen that was histologically negative for lymphoma.
  • With a median follow-up of 5 years, 14 of 25 complete responders have relapsed (56%); median remission duration was 2 years, and overall survival was 61%.
  • ProMACE-CytaBOM plus anti-B4-blocked ricin does not produce durable complete remissions in the majority of patients with indolent lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Immunoconjugates / therapeutic use. Immunotoxins / therapeutic use. Lymphoma / drug therapy. Ricin / therapeutic use
  • [MeSH-minor] Adult. Aged. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / mortality. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Time Factors. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer J. 2000 May-Jun;6(3):135-8 [10882327.001]
  • (PMID = 10882329.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoconjugates; 0 / Immunotoxins; 0 / anti-B4 blocked ricin immunoconjugate; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9009-86-3 / Ricin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; PROMACE-CytaBOM protocol
  •  go-up   go-down


11. Dillman RO, Schreeder MT, Hon JK, Connelly EF, DePriest C, Cutter K: Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother Radiopharm; 2007 Apr;22(2):185-93
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • We conducted a multicenter, community-based phase II trial of PCR biochemotherapy (pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2) every 3 weeks for up to 6 cycles in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • The study was stopped after enrolling 24 patients because of diminished investigator interest after 8 patients discontinued treatment because of adverse events, and 5 others died during treatment.
  • The median age of patients was 69 years; 11 patients were over age 70, and 71% had Rai stage III or IV disease.
  • The response rate among the 17 evaluable patients who completed 3 cycles of therapy was 58% (35%-81%, 95% confidence interval), with 2 complete responders (both greater than 70 years of age) and 7 partial responders.
  • No patients developed progressive disease while receiving PCR.
  • PCR is active in CLL/SLL, but appears to be less active and associated with more complications in the community setting, compared to trials with younger, lower risk patients who travel to academic referral centers for treatment.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Cyclophosphamide / therapeutic use. Delivery of Health Care. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Drug Therapy, Combination. Female. Humans. Immunotherapy / adverse effects. Male. Membrane Glycoproteins. Middle Aged. Rituximab. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7 [17979574.001]
  • (PMID = 17600465.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Membrane Glycoproteins; 143891-49-0 / TI 1 protein, Mustela vison; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G: Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leuk Res; 2010 Apr;34(4):454-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
  • PURPOSE: Resistance to nucleoside analogues agents is likely to be multifactorial and could involve a number of mechanisms affecting drug penetration, metabolism and targeting.
  • In vitro studies of resistant human cell lines have confirmed that human concentrative nucleoside transporter 1 (hCNT1)-deficient cells display resistance.
  • EXPERIMENTAL DESIGN: We applied real-time PCR method to assess the mRNA expression of equilibrative and concentrative nucleoside transporter (hENT1, hCNT1), deoxycytidine and deoxyguanosine kinase (dCK, dGK), 5'-nucleotidase (5'-NT), ribonucleotide reductase catalytic and regulatory (RR1, RR2) subunits in bone marrow cells from 32 patients with Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) who received 2CdA-based chemotherapy.
  • Responses to chemotherapy, were then correlated to the expression of these markers.
  • In univariate analysis, lower expression level of hCNT1 (p=0.0021) and RR2 (p=0.02) correlated with response to chemotherapy.
  • No significant correlation between these genes expression and age, stage of disease was found.
  • This study suggests that nucleotidase expression levels can be used to identify subgroups of WM and SLL patients who will likely respond differently to a 2CdA-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cladribine / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Membrane Transport Proteins / genetics. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / genetics. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Models, Biological. Prognosis. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19647871.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Membrane Transport Proteins; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD: A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol; 2005 Apr;28(2):169-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
  • This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma.
  • This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage.
  • Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas.
  • Thirteen patients were treated with 1 to 6 cycles of chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803012.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Nemets A, Ben Dor D, Barry T, Ducach A, Blumental R, Ben Alon D, Lugassy G: Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine. Leuk Lymphoma; 2003 Dec;44(12):2151-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
  • We report a case of a 52-year-old male who developed classical Hodgkin's lymphoma (HL) four years after diagnosis of stage Rai II (Binet B) chronic lymphocytic leukemia (CLL).
  • Subsequently, he presented with a 6-month history of weight loss and fatigue, and 6 weeks of fever, a progressively enlarged liver and elevated serum LDH level.
  • An inguinal lymph node biopsy revealed both classical Hodgkin's lymphoma, nodular sclerosing type grade 2 and CLL.
  • A bone marrow biopsy showed no Reed-Steinberg cells and an infiltrate composed of only scattered small lymphocytes consistent with CLL.
  • A cytogenic examination of the bone marrow revealed an abnormal karyotype (Y-) in 15% of the cell population.
  • Treatment with MOPP/ABVD was started and fever subsided within 3 days.
  • Since fludarabine has become standard therapy in CLL such Richter's variant could be the result of therapy, an induced prolonged and severe immunosuppression.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / pathology. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Biopsy. Bone Marrow / pathology. Cyclophosphamide / therapeutic use. Disease Progression. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Syndrome. Time Factors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14959863.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


15. Chen ZY, Zhou XY, Zhang TM, Hong XN, Yin JL, Hu XC, Shi DR: [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):183-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
  • OBJECTIVE: To explore the feasibility of semi-nested PCR technique for detection of immunoglobulin heavy chain (IgH) clonal rearrangement in bone marrow of B-cell lymphoma patient and to further evaluate its clinicopathological value.
  • METHODS: Gene clonal rearrangement of IgH was detected by semi-nested PCR using primers of FR2 & FR3A in 105 bone marrow samples of patients with B-cell lymphoma.
  • The PCR detection results were compared with the cytomorphology of bone marrow aspiration biopsy.
  • The correlation between PCR detection results and clinicopathological factors were evaluated.
  • RESULTS: Among 105 cases of B-cell lymphoma, bone marrow involvement was detected by PCR technique in 48 cases (45.7%), while only 22 cases (21.0%) were detected by bone marrow cytological analysis.
  • The incidence of bone marrow involvement at the time of initial diagnosis detected by PCR technique was 30.8% for diffuse large B cell lymphoma (DLBCL), 25.0% for follicular lymphoma (FL), and 100.0% for small lymphocytic lymphoma (SLL), respectively.
  • Bone marrow involvement detected by PCR detection correlated with Ann Arbor stage.
  • Rate of clonal IgH gene rearrangement by PCR in early B-cell lymphoma was lower than that in advanced stage B-cell lymphoma patients (P = 0.02).
  • CONCLUSION: Semi-nested PCR analysis may be an effective method for detection of abnormalities in bone marrow in patients with B-cell lymphoma and is superior to cytomorphology.
  • The positive rate in patients with advanced Ann Arbor stage is higher than that in patients with early Ann Arbor stage, and patients with PCR negative result have more chances to achieved CR after treatment.
  • [MeSH-major] Bone Marrow / pathology. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Immunoglobulin Heavy Chains / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy / methods. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615255.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


16. Chuang SS, Liao YL, Liou CP, Wiggins ML, Ye H, Du MQ, Isaacson PG, Chang CC: Chronic lymphocytic leukemia with paraimmunoblastic transformation - with comparative genomic hybridization and review of the literature. Pathol Res Pract; 2010 Apr 15;206(4):276-81
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia with paraimmunoblastic transformation - with comparative genomic hybridization and review of the literature.
  • Richter's transformation (RT) is the development of a high-grade lymphoma in patients with B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • A 78-year-old Taiwanese male had Rai stage 1 and Binet stage B CLL/SLL involving skin, peripheral blood (PB), and bone marrow (BM) with paraimmunoblastic transformation in the lymph node.
  • Molecular/genomic studies showed the same clonal origin of tumor tissues at various locations with trisomy 12 and a deletion of chromosome 13q14.
  • Interestingly, there seemed to be no additional chromosomal aberrations in the transformed nodal tissue, suggesting that the micro-environment rather than an additional genetic lesion contributed to the transformation.
  • The patient received chemotherapy and was alive with disease after 33.5 months.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymph Nodes / pathology
  • [MeSH-minor] Aged. B-Lymphocytes / pathology. Comparative Genomic Hybridization. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Staging. Trisomy / genetics. Trisomy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19433347.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


17. Park YH, Kim SH, Choi SJ, Ryoo BY, Kang YK, Lee SS: Primary malignant lymphoma of the breast: clinicopathological study of nine cases. Leuk Lymphoma; 2004 Feb;45(2):327-30
Genetic Alliance. consumer health - Primary malignant lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the breast: clinicopathological study of nine cases.
  • Primary lymphoma of the breast is rare, accounting for 1.7-2.2% of extranodal lymphomas and 0.38-0.7% of non-Hodgkin's lymphomas (NHL).
  • The aim of this study was to evaluate the clinicopathological features and treatment outcomes of patients with primary breast lymphomas (PBL).
  • Six cases involved the breast alone (stage IE), whereas 3 cases also involved the ipsilateral axillary lymph nodes (stage IIE).
  • Histopathologic studies revealed a diffuse large B cell lymphoma in 7 cases, marginal zone B cell lymphoma in 1 case, and small lymphocytic lymphoma in 1 case.
  • Immunohistochemical analysis revealed a B-cell phenotype in all cases.
  • There was no uniform approach to the treatment of PBL.
  • Modified radical mastectomy and chemotherapy was performed in 4 cases, modified radical mastectomy and chemoradiotherapy was performed in 1 case, chemoradiotherapy alone, modified radical mastectomy alone, chemotherapy alone, and radiotherapy alone were performed in 1 case each.
  • All cases achieved complete remission, but median overall survival was 12 months, showing very poor prognosis irrespective of the type of treatment modality.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Neoplasms / pathology
  • [MeSH-minor] Adult. Breast. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Phenotype. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15101719.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Wood L, Robinson R, Gavine L, Juritz J, Jacobs P: A single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci; 2007 Aug;37(1):93-102
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single unit lymphoma experience: outcome in a Cape Town academic centre.
  • Diagnosis was according to World Health Organization criteria, prognosis assigned by the international index and therapy risk-stratified with results subject to appropriate statistical methodology.
  • Constitutional symptoms were present in 22%; a quarter had previous chemotherapy and a third some form of irradiation prior to referral.
  • Fifty-seven percent were stage I or II and 21% had nodal disease above and below the diaphragm whilst in the remainder cells were present in the circulation and this included the subset of chronic lymphocytic leukaemia -- small lymphocytic lymphoma.
  • Further adverse factors included any prior treatment, intermediate or high-grade histopathology, risk factors defined by the International Prognostic Index as well as late Rai stages.
  • Analysed by disease category Hodgkin lymphoma (n=17) when managed according to the German Study Group protocols and hairy cell leukaemia (n=10) treated with two chlorodeoxyadenosine -- both had a stable plateau in excess of 90%.
  • Curves for the aggressive or diffuse large B-cell lymphoma (n=44) fell initially to 48%, but relapse continued in stages III and IV to the current level of 18% when receiving cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone on the 21-day schedule.
  • Chronic lymphocytic leukaemia -- small lymphocytic lymphoma (n=58) were initially given pulsed chlorambucil and sustained response was over 90% with low bulk, but declined to reach 30% as prognostic score rose.
  • It is concluded that precise diagnosis, accurate staging and therapy on standardised risk-stratified programmes, delivered uniformly by a single multidisciplinary group, creates the all-important centre effect; matching figures are unlikely to apply outside these disciplined circumstances.
  • It follows that late referral and prior therapy will adversely affect performance status and compromise life span: These alternative approaches are inappropriate and strongly discouraged.
  • [MeSH-major] Hospitals, Private. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Cohort Studies. Developing Countries. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. South Africa. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931976.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Westin EH, Longo DL: T-small cell disorders. Curr Treat Options Oncol; 2001 Jun;2(3):225-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-small cell disorders.
  • A minority (less than 2%) of all lymphoproliferative disorders are derived from small T cells.
  • These include T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, and mycosis fungoides/Sézary syndrome.
  • With the possible exception of early-stage, skin-localized mycosis fungoides, all are considered incurable, although palliation can be achieved with radiation therapy, chemotherapy, biologic therapy, and combinations of these modalities.
  • The T-cell prolymphocytic leukemias, in contrast, are generally refractory to treatment, with a median survival of typically less than 1 year.
  • Although effective therapy remains elusive in most cases, the development of nucleosides as a class of chemotherapeutic agents and biologics, including interferon, monoclonal antibodies, and vitamin A derivatives, offers new hope for at least more effective palliation of these progressive lymphoproliferative disorders.
  • However, rapid improvement in the treatment of these disorders remains hampered by the rarity of these individual entities.
  • More rapid progress in treatment depends on national and international cooperation to accrue patients for definitive trials of sufficient size to evaluate new treatment options quickly.
  • [MeSH-major] Leukemia, T-Cell / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Humans. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1998 Jul;39(1):63-73 [9674399.001]
  • [Cites] Haematologica. 1999 Sep;84(9):809-13 [10477454.001]
  • [Cites] Curr Probl Dermatol. 1990;19:144-9 [2153505.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Arch Dermatol. 1993 Jun;129(6):747-52 [8507078.001]
  • [Cites] Blood. 1994 Sep 15;84(6):1765-74 [8080984.001]
  • [Cites] Curr Probl Cancer. 1990 Nov-Dec;14(6):293-371 [2245651.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):208-15 [3492594.001]
  • [Cites] Oncol Rep. 2000 Nov-Dec;7(6):1197-201 [11032913.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Oct;9(5):1057-76 [8522484.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3245-6 [8874229.001]
  • [Cites] Br J Cancer Suppl. 1975 Mar;2:29-43 [52366.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):543-52 [1599034.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 2:S46-9 [9178839.001]
  • [Cites] Leuk Lymphoma. 1995 Aug;18(5-6):521-7 [8528063.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5496s-5500s [1394162.001]
  • [Cites] Mayo Clin Proc. 1994 Nov;69(11):1085-8 [7967763.001]
  • [Cites] CA Cancer J Clin. 1993 Mar-Apr;43(2):93-115 [8439814.001]
  • [Cites] Am J Pathol. 1988 Aug;132(2):265-77 [3261136.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Leuk Res. 1988;12(1):89-92 [3282128.001]
  • [Cites] Blood. 1998 May 1;91(9):3372-8 [9558395.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Front Radiat Ther Oncol. 1991;25:80-9; discussion 132-3 [1908426.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 21;85(8):658-62 [8468724.001]
  • [Cites] Am J Pathol. 1991 Jun;138(6):1545-52 [1828937.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):647-53 [87277.001]
  • [Cites] Arch Dermatol. 1996 Nov;132(11):1309-13 [8915308.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Leukemia. 1991;5 Suppl 1:46-8 [1716337.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S25-30 [9926234.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):276-89 [10375085.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Clin Lymphoma. 2000 Nov;1 Suppl 1:S45-9 [11707864.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1284-5 [7738636.001]
  • [Cites] Arch Dermatol Res. 1984;276(1):17-26 [6608322.001]
  • [Cites] J Clin Oncol. 1994 Oct;12 (10 ):2051-9 [7931473.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):978-82 [9796726.001]
  • [Cites] Neth J Med. 1990 Aug;37(1-2):37-43 [2215832.001]
  • [Cites] N Engl J Med. 1989 Dec 28;321(26):1784-90 [2594037.001]
  • [Cites] Semin Cutan Med Surg. 2000 Jun;19(2):91-9 [10892710.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Semin Hematol. 1993 Oct;30(4):286-96 [8266115.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2212-8 [10733487.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):158-64 [9487207.001]
  • [Cites] Blood. 1998 Jan 15;91(2):399-405 [9427692.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):927-33 [9326191.001]
  • [Cites] Blood. 1998 Jul 15;92(2):368-73 [9657733.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2385-409 [8839829.001]
  • [Cites] Eur J Immunol. 1988 Dec;18(12):1979-83 [3146510.001]
  • [Cites] Dermatology. 2000;201(1):21-8 [10971054.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):40-50 [10632486.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):793-6 [11050582.001]
  • (PMID = 12057122.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 60
  •  go-up   go-down


20. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk; 2010 Aug;10(4):258-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
  • BACKGROUND: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database.
  • PATIENTS AND METHODS: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan ((90)Y-IT).
  • A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease.
  • According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma.
  • Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months.
  • All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (>or= 3 previous treatments), and 2 had had autologous stem cell transplantation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709661.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


21. Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L: Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. Clin Lymphoma; 2003 Dec;4(3):169-75
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
  • This study explored the efficacy and toxicity of the combination of pentostatin and rituximab, effective single agents in low-grade non-Hodgkin's lymphoma (NHL).
  • Except for day 1, both drugs were administered weekly for 4 weeks, with week 5 off.
  • During week 1 (day 1) only rituximab was given; subsequent weekly treatments included both drugs.
  • Of 60 patients, 58.3% had an Eastern Cooperative Oncology Group performance status (PS) of 0, and 41.7% had PS of 1; 31.7% and 51.7% had stage III or stage IV disease, respectively.
  • Histology included follicular center, follicular, grade I (45%), II (21.7%), III (1.7%), and small lymphocytic (31.7%).
  • Seventeen patients had prior chemotherapy, but no patients had received prior pentostatin or rituximab.
  • Median duration of response was 11 months (range, 2.3-22.2 months); median time to progression was 15 months (range, < 1-25 months).
  • These results suggest the combination of pentostatin/rituximab is well tolerated and active in low-grade lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Rituximab. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14715099.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


22. Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, Hancock BW, Fegan C, Culligan D, Schey S, Morris TC, Lissitchkov T, Oliver JW, Holmlund JT: Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol; 2004 Sep;15(9):1413-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
  • BACKGROUND: The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C alpha in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-six patients received ISIS 3521 (2 mg/kg/day) as a continuous infusion over 21 days of each 28-day cycle.
  • Histological subtypes were low-grade follicular lymphoma (n = 22) and B-cell small lymphocytic lymphoma (n = 4).
  • Twenty-one (81%) had stage III/IV disease.
  • The median number of previous lines of chemotherapy was two (range one to six).
  • There may be a potential role for this agent in combination with conventional chemotherapy for advanced low-grade lymphoma, and further trials are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15319248.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Thionucleotides; 151879-73-1 / ISIS 3521; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down


23. Babovic N, Jelic S, Jovanovic V: Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy? J Exp Clin Cancer Res; 2000 Jun;19(2):149-54
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy?
  • Primary lymphoma of the breast is a rare disease that has been estimated to represent from 0.05% to 0.53% of all malignant breast tumors and approximately 2.2% of all extranodal lymphomas.
  • The aim of this study is to review all cases of primary lymphoma of the breast at the Institute of Oncology and Radiology of Serbia from 1984 to 1996 in order to determine the incidence, patterns of clinical presentation, radiological features, histopathology, mode of therapy and outcome of the disease.
  • Ten cases of primary lymphoma of the breast have been identified during the 12-yr period, presenting 0.05% of all patients with malignant breast disease.
  • Mammography and breast echography were unable to bring a suspicion of lymphoma.
  • Histologically, 6 cases were diffuse large cell, 3 of which with features consistent with immunoblastic lymphoma; 2 were diffuse mixed cells and 2 had small lymphocytic morphology.
  • In 4 out of 5 patients, in the clinical stage corresponding to the "operable breast cancer" category, the ex tempore histological analysis could not differentiate lymphoma from cancer, so that all of them had mastectomy with axillary dissection.
  • Further treatment included chemotherapy for 8 patients.
  • The rarity of this disease, and uneven treatment modalities make prognosis of breast lymphoma difficult.
  • With the limitations of available diagnostic procedures, it appears that most patients with breast lymphoma, in the stage corresponding to the "operable breast cancer" category, will unnecessarily undergo mastectomy and axillary dissection as primary treatment approach.
  • [MeSH-major] Breast Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Mastectomy, Radical
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965810.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


24. Sokol L, Loughran TP Jr: Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. Curr Treat Options Oncol; 2003 Aug;4(4):289-96
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas.
  • Natural killer (NK) cell leukemia and lymphoma represent rare conditions with heterogeneity of biologic behavior, prognosis, and responsiveness to therapy.
  • The initial diagnosis of NK-cell malignancies can be difficult because of the lack of immunophenotypic clonality markers, morphologic heterogeneity, and a poor correlation between cytomorphology and prognosis.
  • Therapeutic recommendations for NK-cell malignancies are derived from retrospective studies or case reports.
  • Immature NK-cell malignancies often have aggressive behavior with poor prognosis, despite administration of acute myeloid leukemia or acute lymphocytic leukemia induction chemotherapy.
  • The use of high-dose chemotherapy with stem cell rescue resulted in a prolonged survival in a small series of patients.
  • NK-cell malignancies originating from cells with mature phenotypes form a spectrum of diseases with distinct prognosis.
  • Patients with aggressive NK-cell leukemia invariably die within several months.
  • Nasal and nasal-like NK/T-cell lymphomas with limited stage disease often respond to radiation therapy alone or combination with chemotherapy and radiation therapy, with 5-year disease-free survival rates ranging from 30% to 75%.
  • Patients with T-cell large granular lymphocyte leukemia or chronic NK-cell lymphoproliferative disease of granular lymphocytes can have an indolent clinical course with long survival without therapy.
  • However, approximately 66% of patients with T-cell large granular lymphocyte leukemia require low-dose chemotherapy with methotrexate or cyclophosphamide or immunosuppressive therapy with glucocorticosteroids or cyclosporine A for symptomatic cytopenias during the course of their disease.
  • [MeSH-major] Killer Cells, Natural. Leukemia / therapy. Lymphoma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Feb;25(2):109-13 [11166825.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1116-9 [1355373.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Cancer Control. 1998 Jan;5(1):25-33 [10761014.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):225-8 [11722437.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Leuk Res. 1989;13(9):735-43 [2796381.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2351-6 [8635042.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(1):91-3 [9012939.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):901-6 [12153184.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Histopathology. 1995 Dec;27(6):581-3 [8838342.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1207-10 [8608206.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1321-2 [10414923.001]
  • [Cites] Br J Haematol. 1990 May;75(1):49-59 [2375924.001]
  • [Cites] Anat Pathol. 1998;3:77-145 [10389582.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5007-9 [12576313.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):128-30 [1967431.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):392-9 [8388175.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):447-50 [11794702.001]
  • [Cites] Radiology. 1997 Aug;204(2):467-70 [9240537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Leuk Res. 1994 Jun;18(6):423-9 [8207960.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2417-28 [9310493.001]
  • [Cites] Cancer. 1995 May 15;75(10):2474-83 [7736391.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] Blood. 1995 May 15;85(10):2654-70 [7742523.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2721-5 [7919384.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Leuk Res. 1999 Jul;23(7):615-24 [10400182.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • (PMID = 12943609.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma; 2003 Jun;44(6):967-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
  • The role of high dose therapy, including autologous stem cell transplantation (ASCT) in indolent non-Hodgkin's lymphomas remains controversial.
  • We evaluated a dose intense regimen of CHOP induction followed by high dose cyclophosphamide consolidation (CHOP-HC) versus CHOP alone in a prospective comparison to assess intensified therapy without ASCT.
  • Twenty-five patients with previously untreated advanced stage indolent NHL were enrolled: follicular lymphoma, grade 1 (11 patients) and grade 2 (8 patients); small lymphocytic lymphoma (5 patients); and lymphoplasmacytic lymphoma (1 patient).
  • Three patients had intra-abdominal stage II, 2 patients with stage III, and 20 patients with stage IV disease.
  • Following induction, responding patients were given consolidation with either high dose cyclophosphamide @ 3 gm/m2 i.v. for 3 doses with G-CSF (weeks 13, 15, 17) or 2 additional cycles of CHOP (weeks 13, 16), stratified by stage and bulk of disease.
  • The median overall survival has not been reached (at 5 years, 77% OS for CHOP-HC versus 83% OS for CHOP alone].
  • There were no treatment-related deaths.
  • With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Rate. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


26. Cowan RA, Murby B, Gunton D, Owens SE, Hoyes KP, Sharma HL, Smith AM, Chang J, van Kessel B, Nuttall PM, Crowther D: Autologous lymphocytes as vectors to target therapeutic radiation, using indium-114m, in patients with lymphoid cell malignancy. Br J Haematol; 2002 Nov;119(2):459-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous lymphocytes as vectors to target therapeutic radiation, using indium-114m, in patients with lymphoid cell malignancy.
  • Autologous lymphocytes provide a potential vector for the delivery of a cytotoxic agent in patients with lymphoid cell malignancy.
  • This report describes a phase I-II study using autologous lymphocytes to target the radionuclide indium-114m ((114m)In) in patients with refractory chronic lymphocytic leukaemia or small lymphocytic non-Hodgkin's lymphoma.
  • Nineteen patients, the majority of whom had been heavily pretreated with conventional chemotherapy and radiotherapy, received between 69 and 211 MBq (114m)In-labelled autologous lymphocytes.
  • The first notable response in every patient was a fall in peripheral lymphocyte count.
  • The indium treatment was not associated with any subjective toxicity, although all patients suffered from myelosuppression, with thrombocytopenia being the dose-limiting factor.
  • This study has demonstrated a significant anti-tumour effect in a group of patients with late-stage highly resistant disease.
  • [MeSH-major] Indium Radioisotopes / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy. Lymphocytes. Radioimmunotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12406086.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indium Radioisotopes
  •  go-up   go-down


27. Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR: Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. J Chemother; 2009 Aug;21(4):434-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
  • This pilot study tested the hypothesis that dose intensity/dose density treatment may improve the response rate and remission duration in patients with advanced low grade lymphomas. ten patients with low grade lymphomas: follicular lymphoma grades I and II, marginal zone lymphoma, and small cell lymphocytic lymphoma with progressive disease were studied.
  • Patients had an ECOG performance of 0-2, and Stage III and IV disease.
  • Patients received a combination of rituximab 375 mg/m(2), cyclophosphamide 1000 mg/m(2), and vincristine 1.4 mg/m(2) (up to a maximal dose of 2 mg), administered by intravenous infusion every two weeks, for ten treatments.
  • Granulocyte colony stimulating factor (G-CSf) was administered on days seven to ten following each cycle of chemotherapy.
  • Untreated patients received an average of 8.3 cycles of therapy (range 5 to 10 cycles).
  • Previously treated patients received an average of 9.3 cycles of therapy (range 6 to 12 cycles).
  • This program is well tolerated with a high CR rate, and may serve as a basis for future trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622463.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 5-P30-CA 072720-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


28. Marucci G, Sgarbanti E, Maestri A, Calandri C, Collina G: Gemcitabine-associated CD8+ CD30+ pseudolymphoma. Br J Dermatol; 2001 Oct;145(4):650-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 69-year-old man with a non-small cell carcinoma of the lung, stage III B, who developed bilateral multiple erythematous lesions in the abdominal-inguinal area following treatment with gemcitabine.
  • Histologically, the lesion was characterized by a heavy lymphocytic infiltrate with large CD30+ cells.
  • The lesion was highly suggestive of cutaneous involvement by malignant lymphoma, but complete regression was observed after cessation of gemcitabine.
  • Although rarely reported, gemcitabine therapy can induce skin lesions.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Pseudolymphoma / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11703296.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD8; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


29. Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP: Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol; 2001;18(2):99-107
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
  • Campath-1H is a humanized monoclonal antibody targeted against the CDw52 membrane antigen of lymphocytes, which causes complement and antibody-dependent cell-mediated cytotoxicity.
  • Campath-1H has been used in B-chronic lymphocytic leukemia (B-CLL), T-prolymphocytic leukemia (T-PLL), and low-grade non-Hodgkin's lymphoma (LGNHL).
  • Because of the antibody's higher activity on circulating lymphocytes, it has been used for in vivo purging of residual disease in B-CLL, followed by autologous stem-cell transplantation.
  • In heavily pretreated advanced stage LGNHL, response is achieved only in 14% of cases with B-phenotype; a 50% response rate is noted in mycosis fungoides.
  • Promising results have been reported in a small number of patients with refractory autoimmune thrombocytopenia of lymphoproliferative disorders.
  • The main complications of Campath-1H treatment are caused by tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 release, usually during the first intravenous infusion, and include fever, rigor, nausea, vomiting, and hypotension responsive to steroids.
  • Immunosupression resulting from normal B- and T-lymphocyte depletion is frequent, resulting in an increased risk for opportunistic infections.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / drug therapy. Leukemia, Prolymphocytic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Dose-Response Relationship, Drug. Humans. Immunosuppression. Infection. Infusions, Intravenous. Interleukin-6 / adverse effects. Interleukin-6 / secretion. Phenotype. Risk Factors. Treatment Outcome. Tumor Necrosis Factor-alpha / adverse effects. Tumor Necrosis Factor-alpha / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1996 Dec 15;98(12):2819-26 [8981930.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):669-72 [9207420.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):151-3 [8611450.001]
  • [Cites] Med Oncol. 2000 Feb;17(1):70-3 [10713664.001]
  • [Cites] Tissue Antigens. 1990 Mar;35(3):118-27 [2165283.001]
  • [Cites] Leuk Lymphoma. 1996 Dec;24(1-2):93-101 [9049965.001]
  • [Cites] Lancet. 1992 Sep 26;340(8822):748-52 [1356177.001]
  • [Cites] Transplantation. 1988 Apr;45(4):753-9 [3282358.001]
  • [Cites] Biotechnology (N Y). 1991 Jan;9(1):64-8 [1367214.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):65-74 [9482528.001]
  • [Cites] Bone Marrow Transplant. 1996 May;17(5):819-24 [8733704.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:113-7 [27463491.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4581-90 [9845524.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 5):12-7 [10528911.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):754-60 [10792280.001]
  • [Cites] J Clin Pathol. 1994 Apr;47(4):313-7 [8027367.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):219-35 [7612488.001]
  • [Cites] Blood. 1983 Oct;62(4):873-82 [6349718.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):506-15 [7734348.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):52-7 [10561018.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):198-208 [10319388.001]
  • [Cites] Blood. 1989 May 1;73(6):1431-9 [2713487.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):305-8 [8704678.001]
  • [Cites] Blood. 1984 Nov;64(5):1085-93 [6333257.001]
  • [Cites] Lancet. 1988 Dec 17;2(8625):1394-9 [2904526.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):61-4 [7858503.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):1103-6 [8782148.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3257-63 [9779699.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] Eur J Immunol. 1991 Jul;21(7):1677-84 [1711975.001]
  • [Cites] Br J Haematol. 1993 Jul;84(3):542-4 [8217808.001]
  • [Cites] Lancet. 1993 Apr 17;341(8851):1037 [8096935.001]
  • [Cites] Mol Biol Med. 1983 Oct;1(3):305-19 [6390085.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):104-14 [10319379.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):479-86 [9250818.001]
  • [Cites] Exp Hematol. 1999 Jul;27(7):1210-8 [10390197.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] Eur J Immunol. 1988 Oct;18(10):1507-14 [2973413.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):353-9 [8914801.001]
  • [Cites] Transplantation. 1999 Feb 27;67(4):620-6 [10071037.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):5-13 [9020367.001]
  • [Cites] N Engl J Med. 1990 Jul 26;323(4):250-4 [2366834.001]
  • [Cites] Leuk Lymphoma. 1990;2(3-4):179-93 [27456733.001]
  • [Cites] Curr Opin Hematol. 1998 Jul;5(4):237-43 [9747629.001]
  • [Cites] Nature. 1988 Mar 24;332(6162):323-7 [3127726.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):209-16 [10319389.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • (PMID = 11778765.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 3A189DH42V / alemtuzumab
  • [Number-of-references] 60
  •  go-up   go-down


30. Schiffer CA: Treatment of high-grade lymphoid malignancies in adults. Semin Hematol; 2001 Oct;38(4 Suppl 10):22-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-grade lymphoid malignancies in adults.
  • High-grade, B-lineage lymphoproliferative disorders can have a leukemic (acute lymphocytic leukemia [ALL] French-American-British [FAB] stage L-3), a lymphomatous (Burkitt's or small noncleaved [SNC]), or often a mixed clinical presentation in adults.
  • Manifestations of these diseases in both adults and children include a propensity for abdominal and CNS involvement and a high incidence of metabolic abnormalities due to rapid cell growth and turnover, which are acutely exacerbated by treatment.
  • Numerous studies show that FAB L-3, Burkitt's lymphoma (BL), and SNC are among the most curable of the multiple leukemia/lymphoma subtypes if treated appropriately.
  • At least 50% of adults with these disorders are cured with the use of short-term intensive chemotherapeutic regimens, with treatment failure a consequence of both drug resistance and an inability of older adults to tolerate the side effects of therapy.
  • Future studies should focus on better characterizing the patient populations to help identify the patients most likely to benefit from these aggressive regimens, as well as those who might require high-dose therapy with stem-cell transplantation.
  • [MeSH-major] Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / blood. Burkitt Lymphoma / complications. Burkitt Lymphoma / drug therapy. Humans. Metabolic Diseases / blood. Metabolic Diseases / etiology. Treatment Outcome. Tumor Lysis Syndrome / blood. Tumor Lysis Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11694948.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down






Advertisement